Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.34 | N/A | -13.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.34 | N/A | -13.33% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions affecting performance. They highlighted a commitment to enhancing operational strategies but did not provide detailed future plans.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future growth strategies were discussed, but specifics were limited.
Biocryst Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue data and guidance updates may leave investors uncertain about the company's near-term prospects. The stock's reaction reflects cautious sentiment in light of the reported EPS miss and management's defensive tone.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSOLIDATED EDISON
Nov 4, 2019